vs
Side-by-side financial comparison of Farmland Partners Inc. (FPI) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $20.7M, roughly 1.1× Farmland Partners Inc.). Farmland Partners Inc. runs the higher net margin — 103.4% vs -416.2%, a 519.6% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -3.5%). Over the past eight quarters, Farmland Partners Inc.'s revenue compounded faster (31.4% CAGR vs -10.8%).
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FPI vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.7M | $23.0M |
| Net Profit | $21.4M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | 103.4% | -416.2% |
| Revenue YoY | -3.5% | 78.8% |
| Net Profit YoY | -63.5% | 25.7% |
| EPS (diluted) | $0.44 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.7M | $23.0M | ||
| Q3 25 | $11.3M | $13.8M | ||
| Q2 25 | $10.0M | $14.2M | ||
| Q1 25 | $10.3M | $16.6M | ||
| Q4 24 | $21.5M | $12.9M | ||
| Q3 24 | $13.3M | $9.1M | ||
| Q2 24 | $11.4M | $7.0M | ||
| Q1 24 | $12.0M | $28.9M |
| Q4 25 | $21.4M | $-95.8M | ||
| Q3 25 | $483.0K | $-101.3M | ||
| Q2 25 | $7.6M | $-101.3M | ||
| Q1 25 | $2.0M | $-114.3M | ||
| Q4 24 | $58.7M | $-128.9M | ||
| Q3 24 | $1.8M | $-135.7M | ||
| Q2 24 | $-2.0M | $-147.0M | ||
| Q1 24 | $1.4M | $-107.4M |
| Q4 25 | — | -428.9% | ||
| Q3 25 | 4.3% | -808.9% | ||
| Q2 25 | 78.2% | -772.2% | ||
| Q1 25 | 20.6% | -726.6% | ||
| Q4 24 | — | -1059.9% | ||
| Q3 24 | 13.9% | -1589.0% | ||
| Q2 24 | -17.9% | -1998.6% | ||
| Q1 24 | 11.9% | -394.0% |
| Q4 25 | 103.4% | -416.2% | ||
| Q3 25 | 4.3% | -735.2% | ||
| Q2 25 | 76.3% | -710.8% | ||
| Q1 25 | 19.9% | -687.6% | ||
| Q4 24 | 273.6% | -1001.2% | ||
| Q3 24 | 13.5% | -1489.5% | ||
| Q2 24 | -17.5% | -2112.6% | ||
| Q1 24 | 11.5% | -371.3% |
| Q4 25 | $0.44 | $-0.81 | ||
| Q3 25 | $0.00 | $-0.92 | ||
| Q2 25 | $0.14 | $-0.98 | ||
| Q1 25 | $0.03 | $-1.10 | ||
| Q4 24 | $1.09 | $-1.27 | ||
| Q3 24 | $0.02 | $-1.34 | ||
| Q2 24 | $-0.06 | $-1.52 | ||
| Q1 24 | $0.01 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | $161.6M | — |
| Stockholders' EquityBook value | $467.4M | $671.4M |
| Total Assets | $719.1M | $842.1M |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $170.4M | — | ||
| Q2 25 | $193.4M | — | ||
| Q1 25 | $202.6M | — | ||
| Q4 24 | $204.6M | — | ||
| Q3 24 | $394.0M | — | ||
| Q2 24 | $393.0M | — | ||
| Q1 24 | $383.0M | — |
| Q4 25 | $467.4M | $671.4M | ||
| Q3 25 | $457.3M | $748.4M | ||
| Q2 25 | $473.5M | $715.3M | ||
| Q1 25 | $492.2M | $779.9M | ||
| Q4 24 | $494.6M | $872.0M | ||
| Q3 24 | $519.4M | $962.6M | ||
| Q2 24 | $521.5M | $971.1M | ||
| Q1 24 | $526.7M | $1.0B |
| Q4 25 | $719.1M | $842.1M | ||
| Q3 25 | $738.5M | $925.3M | ||
| Q2 25 | $776.7M | $898.9M | ||
| Q1 25 | $810.5M | $986.2M | ||
| Q4 24 | $869.6M | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $1.0B | $1.3B |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.4M | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.4M | $-69.3M | ||
| Q3 25 | $-2.0M | $-76.9M | ||
| Q2 25 | $-2.2M | $-99.6M | ||
| Q1 25 | $6.4M | $-148.9M | ||
| Q4 24 | $16.1M | $-85.2M | ||
| Q3 24 | $-4.3M | $-84.8M | ||
| Q2 24 | $-6.1M | $-58.2M | ||
| Q1 24 | $11.9M | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FPI
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
